thrombectomy
(3)
Inquis Medical, Inc.
Inquis Medical is a Silicon Valley medical device company founded in 2020 by serial medtech entrepreneurs Vahid and Mojgan Saadat. Its flagship AVENTUS Precision Thrombectomy System removes blood clots from patients with pulmonary embolism (PE) and deep vein thrombosis (DVT), using proprietary TrueClot tissue-sensing technology that gives physicians real-time feedback to distinguish blood, clot, and vessel wall while minimizing blood loss through autologous blood reinfusion. Backed by $115M in total funding including a $75M Series C in January 2026, the company is scaling nationwide commercial adoption after winning FDA 510(k) clearance for PE in 2025.
InterVene, Inc.
InterVene, Inc. is a Redwood City, California vascular medical device company building catheter-based tools for severe venous disease. Born out of Stanford Biodesign, it first pioneered BlueLeaf, a non-implantable system that forms new vein valves from a patient's own tissue, then pivoted its lead product to Recana, an FDA-cleared thrombectomy catheter system that clears venous in-stent restenosis and native-vessel obstructions - a stubborn problem that leaves stented patients with debilitating complications and few good options.
Nventric, Inc.
Nventric, Inc. is a medical device company and contract development and manufacturing organization (CDMO) headquartered in Arcadia, California, with operations in Seoul, South Korea. Founded in 2019 by engineers with backgrounds at Abbott Vascular and Johnson & Johnson, Nventric designs and builds minimally invasive vascular devices - covering neurovascular, coronary, and electrophysiology applications - from concept through scalable, ISO 13485-certified manufacturing. Its own-branded neurovascular line, including the ULTRIVA stent retriever and EVOGLIDE distal access catheter, targets acute ischemic stroke, while its OEM/CDMO services help device companies move products from prototype to commercialization.